Is seasonality of suicides stronger in victims with hospital-treated atopic disorders?

Thread view:

Enable EMail Alerts

Start New Thread

Thread rating:

Twittering One - 31 Mar 2007 02:52 GMT

Psychiatry Res. 2004 Apr 30;126(2):167-75.
Is seasonality of suicides stronger in victims with hospital-treated
atopic disorders?

Department of Forensic Medicine, University of Oulu, Box 5000, 90014
Oulu, Finland.

The aim of the present study was to test whether the seasonal
distribution of suicides differed between atopic and non-atopic
suicide victims. A cross-sectional comparison of the semi-annual and
seasonal distribution of suicides was made by using a 13-year database
of all suicides (1296 males, 289 females) committed during the years
1988-2000 in the province of Oulu in Northern Finland.

During the first half of the year, the proportion of suicides among
atopic patients was significantly higher than that linked with non-
atopic patients.

Of all atopic patients, 72% committed suicide during the first and 28%
during the second half of the year. Suicides among victims without any
atopic disorders followed a uniform seasonal distribution throughout
the year (50 vs. 50%).

The exacerbation of an atopic disorder may increase the risk of
suicide in spring; something that should be taken note of in clinical
work.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstra
ctPlus&list_uids=15123396&query_hl=1&itool=pubmed_DocSum

Reply to this Message

Twittering One - 31 Mar 2007 03:07 GMT

Psychosom Med. 2002 Sep-Oct;64(5):835-40.
Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-
SR: a pilot study.

Department of Psychiatry, the University of Alabama at Birmingham
School of Medicine, Birmingham, AL 35294-0018, USA.
jgmodell@earthlink.com

OBJECTIVE: To determine whether the antidepressant bupropion may be
useful in treating atopic dermatitis and psoriasis in nondepressed
patients. METHOD: Ten nondepressed subjects with atopic dermatitis and
10 with psoriasis completed a single-track, open-label treatment
protocol with bupropion-SR in doses of 150 mg/day and 300 mg/day,
administered sequentially for 3 weeks each, followed by a 3-week wash-
out. Treatment response was assessed at the end of each 3-week
period.

RESULTS: Six of the 10 subjects with atopic dermatitis showed a
reduction in affected body surface area by the end of 6 weeks of
bupropion treatment, with affected area increasing toward the prestudy
baseline in all responders following bupropion discontinuation-a
highly significant treatment effect (p =.0003). Of the 10 subjects
having psoriasis, improvement over baseline after 6 weeks of treatment
was seen in eight subjects, with coverage increasing toward the
prestudy baseline in the responders following bupropion
discontinuation (p =.001). Average reduction in affected area in the
responders at week 6 of treatment was approximately 50% in both
groups.

CONCLUSIONS: The generally good tolerability and relative safety of
bupropion-SR makes a trial of this agent worthwhile in patients with
atopic dermatitis or psoriasis who have failed treatment with more
conventional medications.

Normalization by bupropion of potentially causative neuroendocrine,
immunologic, or catecholaminergic abnormalities in both of these
dermatologic disorders is a possible mechanism of action for the
observed salutary effects of this drug on our subjects' skin disease.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstra
ctPlus&list_uids=12271115&query_hl=26&itool=pubmed_docsum

Reply to this Message

Twittering One - 31 Mar 2007 03:08 GMT

Pharmacopsychiatry. 2006 Nov;39(6):229.
Bupropion in atopic dermatitis.

Bupropion is an antidepressive drug whose main mechanism of action
seems to be the inhibition of noradrenaline and dopamine recapture. We
present a clinical case of a 50-year-old person with severe atopic
dermatitis (A.D.) and without psychiatric symptoms associated, who was
casually treated with bupropion with very good results. The mechanisms
of action are not yet known, given the diversity of the implied
physiopathology mechanisms: genetic, immunological, inflammatory, etc.
The use of bupropion in serious and resistant cases to other
treatments could constitute a pertinent therapeutic alternative.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstra
ctPlus&list_uids=17124645&query_hl=26&itool=pubmed_docsum\

Reply to this Message

Twittering One - 31 Mar 2007 03:10 GMT

Dexedrine works even better and treats AD[Hi!]D too ~ !

Reply to this Message

Twittering One - 31 Mar 2007 03:19 GMT

Clin Allergy. 1983 May;13(3):241-6.
Serum dopamine beta-hydroxylase and free fatty acids in exercise-
induced asthma.

Serum dopamine beta-hydroxylase activity, which is thought to reflect
noradrenaline secretion, and free fatty acid level were measured in
twenty atopic asthmatic children, of whom ten had exercise-induced
asthma (EIA), after exercise on the treadmill.

There was a significant decrease in the level of serum dopamine beta-
hydroxylase activity in the asthmatics who developed EIA and this
closely accompanied the onset of airflow obstruction. There was no
change in the free fatty acid levels. In contrast, the asthmatics, who
did not have EIA showed a significant rise in the levels of dopamine
beta-hydroxylase activity and free fatty acids after the same exercise
task.

Our results suggest that the atopic children studied, who developed
EIA, may have had an impaired noradrenaline response to exercise. It
is further suggested that this impaired noradrenaline secretion may
facilitate mediator release and contribute to the airflow obstruction
in EIA.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstra
ctPlus&list_uids=6851073&query_hl=26&itool=pubmed_docsum

Reply to this Message